In its many embodiments, the present invention provides a novel class of
imidazo[1,2-a]pyrazine compounds as inhibitors of cyclin dependent
kinases, methods of preparing such compounds, pharmaceutical compositions
containing one or more such compounds, methods of preparing
pharmaceutical formulations comprising one or more such compounds, and
methods of treatment, prevention, inhibition, or amelioration of one or
more diseases associated with the CDKs using such compounds or
pharmaceutical compositions.
